Beta Drugs is proposing an Initial Public Offering (IPO) on the NSE SME platform under the SME category.
Subscription opens 29 Sep 2017, closes 04 Oct 2017. Listing expected 12 Oct 2017. Apply via ASBA or UPI.
Beta Drugs proposes to utilise the net proceeds from the Issue for the following objects:
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 1,600 | ₹136,000 |
| Retail (Max) | 13 | 20,800 | ₹1,768,000 |
| sNII (Min) | 14 | 22,400 | ₹1,904,000 |
| bNII (Min) | 68 | 108,800 | ₹9,248,000 |
| Particulars | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|
| Revenue from Operations | N/A | N/A | N/A |
| EBITDA | N/A | N/A | N/A |
| Profit After Tax (PAT) | N/A | N/A | N/A |
| Net Worth | N/A | N/A | N/A |
| Total Assets | N/A | N/A | N/A |
| Reserves & Surplus | N/A | N/A | N/A |
| Total Borrowings | N/A | N/A | N/A |